

# Study to investigate the combination of methylprednisolone and interferon-beta in the treatment of multiple sclerosis

<b>Submission date</b> 24/04/2009	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 24/04/2009	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 30/06/2009	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Per Soelberg Sørensen

**Contact details**  
Danish Multiple Sclerosis Research Center  
Department of Neurology 2082  
Copenhagen University Hospital Rigshospitalet  
Copenhagen  
Denmark  
DK-2100  
+45 3545 2080  
per.soelberg.soerensen@rh.regionh.dk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

N/A

## Study information

### Scientific Title

Nordic trial of methylprednisolone as add-on therapy to interferon-beta for the treatment of relapsing-remitting multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group, multicentre trial

### Acronym

NORMIMS

### Study objectives

Interferon-beta (IFN-beta) is the approved standard therapy in relapsing-remitting multiple sclerosis (MS). The effect of IFN-beta in relapsing-remitting MS is primarily directed against the Th1-driven inflammatory demyelinating attack. IFN-beta may interfere with cell trafficking by decreasing the expression of adhesion molecules and inhibit matrix metalloproteinases; reduce the expression of major histocompatibility complex (MHC) II molecules on antigen presenting cells; inhibit pro-inflammatory cytokines and induce anti-inflammatory cytokines. However, the effect of IFN-beta on clinical disease activity is only moderate and many patients have only a partial treatment response.

The possible beneficial effect of intravenous methylprednisolone in delaying the onset of MS after optic neuritis has been suggested to be due to its anti-inflammatory and/or immune regulatory activity. Since IFN-beta also has such biological and immunological properties it seems justified to investigate the potential effect of the combination of methylprednisolone and IFN-beta in patients with relapsing-remitting MS. Further methylprednisolone might have a positive effect on the occurrence of side effects to IFN-beta treatment and might reduce the occurrence of neutralising antibodies against IFN-beta. Adjuvant intermittent treatment with methylprednisolone is easy to administer, well tolerated and relatively inexpensive. The objective of the study is to compare the effect of methylprednisolone given at 4-week intervals with the effect of placebo in patients treated with IFN-beta-1a who during therapy have shown clinical activity.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

1. Scientific Ethics Committee of Copenhagen approved on the 23rd May 2003 (ref: KF 02-012 /03)
2. Danish Regulatory Authorities (Danish Medicinal Agency) approved on the 30th May 2003 (ref: 2612-2236)

### Study design

Randomised double-blind placebo-controlled parallel-group multicentre trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

**Study setting(s)**

Not specified

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Relapsing-remitting multiple sclerosis

**Interventions**

Methylprednisolone 100 mg tablets or identically appearing placebo tablets. Dose and administration: 2 tablets after the morning meal on 5 consecutive days at 4-week intervals for at least 96 weeks (extension to 144 weeks possible).

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Methylprednisolone, interferon-beta

**Primary outcome measure**

The mean number of documented relapses per patient per year at 96 weeks. A documented relapse was defined as the appearance of a new or worsening of old neurological symptoms or signs, in the absence of fever, persisting for more than 48 hours and causing objective changes on neurological examination and preceded by a period of more than 30 days with a stable or improving condition. Changes in bowel and bladder or cerebral functions should not have been solely responsible for a relapse.

**Secondary outcome measures**

1. The mean number of documented relapses per patient per year at 48 weeks
2. The occurrence of neutralising antibodies at 96 weeks
3. Changes in the Multiple Sclerosis Functional Composite (MSFC) score
4. The time to a permanent increase in disability of 1.0 point as measured by the Extended Disability Status Score (EDSS) and confirmed at 2 consecutive visits with an interval of 24 weeks
5. The number of active lesions (new or enlarging lesions) on T2 weighted magnetic resonance imaging (MRI)

**Overall study start date**

25/08/2003

**Completion date**

10/12/2007

# Eligibility

## Key inclusion criteria

1. Males and females between the age of 18 and 55 years (both included)
2. Has multiple sclerosis according to the McDonald criteria and suffers from clinically definite relapsing-remitting MS according to the Poser criteria
3. Has a disability equivalent to Expanded Disability Status Scale (EDSS) of 5.5 or less
4. Has been on treatment with IFN-beta-1a (Rebif®) for at least 1 year and has received IFN-beta-1a (Rebif®) 44 µg three times weekly for at least 1 month
5. Has shown clinical activity defined as at least one relapse during the previous 12 months and thereby is classified as a patient with partial treatment response. A historical relapse may be accepted as qualifying as judged by the treating physician.
6. Is prepared to and considered able to follow the protocol during the whole study period and to attend the planned visits
7. Female of childbearing potential must use adequate contraceptive methods and must have negative pregnancy test results
8. Has given written informed consent

## Participant type(s)

Patient

## Age group

Adult

## Lower age limit

18 Years

## Sex

Both

## Target number of participants

Three hundred (300) patients were planned to be enrolled

## Key exclusion criteria

1. Has received treatment with lymphoid irradiation, mitoxantrone, cyclophosphamide, or long-term systemic glucocorticoids
2. Has received treatment with azathioprine, cyclosporine, glatiramer acetate, or other immunosuppressive agents or intravenous immunoglobulin within 6 months prior to inclusion in the study
3. Has changed IFN-beta preparation or dose within 3 months of inclusion in the study
4. Has received treatment with systemic glucocorticoids (relapse treatment) or adrenocorticotrophic hormone (ACTH) within 8 weeks prior to inclusion in the study
5. Has experienced a relapse within one month prior to the inclusion in the study
6. Has converted to secondary progressive MS
7. Has a history of peptic ulcer or present symptoms of dyspepsia
8. Has suffered from major depression or any other psychiatric disorder that would preclude safe participation in the study
9. Has diabetes mellitus
10. Has alcohol or drug abuse
11. Has cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or

advanced ischaemic heart disease (New York Heart Association [NYHA] Functional Classification III or IV), or malignant hypertension

12. Has renal insufficiency

13. Has aspartate aminotransferase (ASAT) greater than 2.5 x normal upper limit

14. Has leucopenia less than 2500 leucocytes per microlitre or thrombocytopenia less than 100,000 thrombocytes per microlitre

15. Has any medical illness requiring treatment with systemic corticosteroids

16. Has any systemic disease, which can influence his/her safety and compliance, or the evaluation of the disability

17. Has formerly shown severe reactions against corticosteroids

18. Is pregnant or breast-feeding

19. Has epilepsy not under control by anti-epileptic drug (AED)

#### **Date of first enrolment**

25/08/2003

#### **Date of final enrolment**

10/12/2007

## **Locations**

#### **Countries of recruitment**

Denmark

Finland

Norway

Sweden

#### **Study participating centre**

**Danish Multiple Sclerosis Research Center**

Copenhagen

Denmark

DK-2100

## **Sponsor information**

#### **Organisation**

Danish Multiple Sclerosis Research Center (Denmark)

#### **Sponsor details**

c/o Professor Per Soelberg Sørensen

Department of Neurology 2082

Copenhagen University Hospital Rigshospitalet

Copenhagen

Denmark  
DK-2100  
+45 3545 2080  
per.soelberg.soerensen@rh.regionh.dk

**Sponsor type**

Hospital/treatment centre

**Website**

<http://www.ms-research.dk/>

**ROR**

<https://ror.org/04anq5q02>

## Funder(s)

**Funder type**

Industry

**Funder Name**

Merck Serono (Denmark) - non-conditional grant; investigator-initiated and investigator-driven study

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/06/2009		Yes	No